Company news
Explain this story: Exagen leaves S&P Global BMI Index: what it means for Exagen stock
Exagen Inc. has been removed from the S&P Global BMI Index, an event that could impact passive fund demand for its stock. This change comes as the company reports strong operating figures, including a 16% year-over-year revenue increase in Q2 2026 and raised full-year revenue guidance, driven by growth in its AVISE testing products for autoimmune conditions. Investors are now focused on whether Exagen can sustain its operational improvements in the latter half of the year.
OtherAD HOC NEWSSector and industry: Market-wideTell me moreShow less
We have not explained this story yet. The original headline, summary and link are below.
Exagen Inc. has been removed from the S&P Global BMI Index, an event that could impact passive fund demand for its stock. This change comes as the company reports strong operating figures, including a 16% year-over-year revenue increase in Q2 2026 and raised full-year revenue guidance, driven by growth in its AVISE testing products for autoimmune conditions. Investors are now focused on whether Exagen can sustain its operational improvements in the latter half of the year.
Published Oct 5, 2026, 19:58 ET · on this site +1h 12m